AGEN
Agenus Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.26
+0.18%Aug 26, 2026, 14:05 UTC
Agenus announced the peer-reviewed publication of updated results from the Phase 2 NEST trial of neoadjuvant botensilimab and balstilimab in resectable colon cancer, reporting deep pathologic responses and no observed recurrences.
Source:Aug 18, 2026, 00:00 UTC
Agenus Inc. amended and restated its existing promissory note with Ocean 1181 LLC, extending the maturity to November 30, 2029, maintaining a 13.0% annual interest rate, and adding a $247,500 extension fee, half of which is payable in common stock.
Aug 6, 2026, 11:30 UTC
Agenus Inc. advanced its Phase 3 ROBBIN trial of botensilimab plus balstilimab in neoadjuvant MSS colon cancer.
Source:Jul 13, 2026, 14:02 UTC
Agenus announced a shift in development focus to a Phase 3 registrational trial of neoadjuvant botensilimab plus balstilimab (BOT/BAL) in high-risk stage 2 and stage 3 microsatellite stable colon cancer.
Source:Jul 13, 2026, 13:48 UTC
Agenus completed a securities purchase agreement for a private placement of $85 million, with warrants that could raise an additional $255 million, for total potential proceeds of up to $340 million.
Jul 6, 2026, 00:00 UTC
Agenus Inc amended its $5.09 million senior subordinated promissory notes, extending the maturity date from June 20, 2026 to February 18, 2027, and extended the expiration of existing warrants while issuing new warrants for 56,525 common shares.